Abivax Shares Drop Despite Positive Ulcerative Colitis Drug Trial Results
Despite positive Phase 3 maintenance trial results for its ulcerative colitis drug obefazimod, Abivax (ABVX) shares fell sharply in premarket trading due to concerns over potential cancer-related side effects. The medicine showed a clinically meaningful efficacy and achieved a remission rate of about 40%.
Tickers: $ABVX
Topics: pharmaceuticals stock market reaction ulcerative colitis